Abbott Laboratories Price Target Raised to $49.00 at Jefferies Group (ABT)
Investment analysts at Jefferies Group increased their target price on shares of Abbott Laboratories (NYSE:ABT) from $48.00 to $49.00 in a note issued to investors on Thursday, Analyst Ratings Network.com reports. The firm currently has a “buy” rating on the stock. Jefferies Group’s price objective indicates a potential upside of 25.00% from the company’s current price.
Other equities research analysts have also recently issued reports about the stock. Analysts at Barclays raised their price target on shares of Abbott Laboratories from $38.00 to $40.00 in a research note to investors on Thursday. They now have an “equal weight” rating on the stock. Separately, analysts at Morgan Stanley upgraded shares of Abbott Laboratories from an “equal weight” rating to an “overweight” rating in a research note to investors on Monday. They now have a $45.00 price target on the stock. Finally, analysts at Deutsche Bank raised their price target on shares of Abbott Laboratories from $37.00 to $39.00 in a research note to investors on Monday, December 16th. They now have a “hold” rating on the stock. One research analyst has rated the stock with a sell rating, seven have given a hold rating and ten have given a buy rating to the company. The stock currently has an average rating of “Buy” and an average target price of $39.14.
Abbott Laboratories (NYSE:ABT) traded up 0.18% on Thursday, hitting $39.27. 4,996,794 shares of the company’s stock traded hands. Abbott Laboratories has a 52-week low of $32.55 and a 52-week high of $39.69. The stock’s 50-day moving average is $37.86 and its 200-day moving average is $36.04. The company has a market cap of $60.719 billion and a price-to-earnings ratio of 20.49.
Abbott Laboratories (NYSE:ABT) last released its earnings data on Wednesday, October 16th. The company reported $0.55 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.52 by $0.03. The company had revenue of $5.37 billion for the quarter, compared to the consensus estimate of $5.46 billion. During the same quarter in the previous year, the company posted $1.30 earnings per share. The company’s revenue for the quarter was up 2.0% on a year-over-year basis. On average, analysts predict that Abbott Laboratories will post $2.01 earnings per share for the current fiscal year.
Abbott Laboratories (NYSE:ABT), is engaged in the discovery, development, manufacture, and sale of a portfolio of science-based health care products.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.